mirvetuximab
ImmunoGen
['ovarian', 'mirvetuximab', 'gyn', 'mirasol']
in the phase 3 mirasol study, the antibody-drug conjugate mirvetuximab soravtansine-gynx produced an overall survival benefit in women with platinum-resistant ovarian cancer. #asco23 
Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME.